Amyotrophic lateral sclerosis (ALS) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: AB681DEB789EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Amyotrophic lateral sclerosis (ALS) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic lateral sclerosis (ALS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Amyotrophic lateral sclerosis (ALS) Understanding

The DelveInsight Amyotrophic lateral sclerosis (ALS) epidemiology report gives a thorough understanding of the Amyotrophic lateral sclerosis (ALS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Amyotrophic lateral sclerosis (ALS) in the US, Europe, and Japan. The report covers the detailed information of the Amyotrophic lateral sclerosis (ALS) epidemiology scenario in seven major countries (US, EU5, and Japan).

Amyotrophic lateral sclerosis (ALS) Epidemiology Perspective by DelveInsight

The Amyotrophic lateral sclerosis (ALS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Amyotrophic lateral sclerosis (ALS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Amyotrophic lateral sclerosis (ALS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Amyotrophic lateral sclerosis (ALS) Detailed Epidemiology Segmentation

The Amyotrophic lateral sclerosis (ALS) epidemiology covered in the report provides historical as well as forecasted Amyotrophic lateral sclerosis (ALS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Amyotrophic lateral sclerosis (ALS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Amyotrophic lateral sclerosis (ALS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Amyotrophic lateral sclerosis (ALS) Epidemiology Report and Model provide an overview of the global trends of Amyotrophic lateral sclerosis (ALS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Amyotrophic lateral sclerosis (ALS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Amyotrophic lateral sclerosis (ALS)
• The report provides the segmentation of the Amyotrophic lateral sclerosis (ALS) epidemiology

Report Highlights

• 11-year Forecast of Amyotrophic lateral sclerosis (ALS) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Amyotrophic lateral sclerosis (ALS)
• Cases of Amyotrophic lateral sclerosis (ALS) by Mutation Types
• Amyotrophic lateral sclerosis (ALS) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Amyotrophic lateral sclerosis (ALS)?
• What are the key findings pertaining to the Amyotrophic lateral sclerosis (ALS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Amyotrophic lateral sclerosis (ALS) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Amyotrophic lateral sclerosis (ALS)?
• What are the currently available treatments of Amyotrophic lateral sclerosis (ALS)?

Reasons to buy

The Amyotrophic lateral sclerosis (ALS) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Amyotrophic lateral sclerosis (ALS) market
• Quantify patient populations in the global Amyotrophic lateral sclerosis (ALS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Amyotrophic lateral sclerosis (ALS) therapeutics in each of the markets covered
• Understand the magnitude of Amyotrophic lateral sclerosis (ALS) population by its epidemiology
• The Amyotrophic lateral sclerosis (ALS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

3. AMYOTROPHIC LATERAL SCLEROSIS (ALS): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Amyotrophic lateral sclerosis (ALS) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Amyotrophic lateral sclerosis (ALS) Treatment and Management
6.2. Amyotrophic lateral sclerosis (ALS) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Amyotrophic lateral sclerosis (ALS) Epidemiology in 7MM (2019-2032)
Table 2: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Amyotrophic lateral sclerosis (ALS) Epidemiology in the United States (2019-2032)
Table 4: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Amyotrophic lateral sclerosis (ALS) Epidemiology in Germany (2019-2032)
Table 6: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Amyotrophic lateral sclerosis (ALS) Epidemiology in France (2019-2032)
Table 8: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Amyotrophic lateral sclerosis (ALS) Epidemiology in Italy (2019-2032)
Table 10: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Amyotrophic lateral sclerosis (ALS) Epidemiology in Spain (2019-2032)
Table 12: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Amyotrophic lateral sclerosis (ALS) Epidemiology in the United Kingdom (2019-2032)
Table 14: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Amyotrophic lateral sclerosis (ALS) Epidemiology in Japan (2019-2032)
Table 16: Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Amyotrophic lateral sclerosis (ALS) Epidemiology in 7MM (2019-2032)
Figure 2 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Amyotrophic lateral sclerosis (ALS) Epidemiology in the United States (2019-2032)
Figure 4 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Amyotrophic lateral sclerosis (ALS) Epidemiology in Germany (2019-2032)
Figure 6 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Amyotrophic lateral sclerosis (ALS) Epidemiology in France (2019-2032)
Figure 8 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Amyotrophic lateral sclerosis (ALS) Epidemiology in Italy (2019-2032)
Figure 10 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Amyotrophic lateral sclerosis (ALS) Epidemiology in Spain (2019-2032)
Figure 12 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Amyotrophic lateral sclerosis (ALS) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Amyotrophic lateral sclerosis (ALS) Epidemiology in Japan (2019-2032)
Figure 16 Amyotrophic lateral sclerosis (ALS) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report